🇺🇸 split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose in United States

split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose (split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose in United States?

Sinovac Biotech Co., Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.